Bivalirudin in the Treatment of Coronary Artery Disease by Jayasinghe, Rohan et al.
67
Angioedema ereditario da carenza di C1-inibitore: terapia sostitutiva con concentrato plasmatico
Disclosure
RJ has received advisory honoraria from The Medicines 
company. RM and VS have no conflicts of interest
Corresponding author
Rohan Jayasinghe MBBS, FRACP, PhD
Email: roheart2000@yahoo.com
Rohan Jayasinghe 1,2, Ryan Maxwell 3, Vaishnavi Sridhar 4
1 Head of Cardiology, Gold Coast University Hospital
2 Professor of Cardiology, Griffith University, Queensland, Australia
3 Senior Registrar – Cardiology Department, Gold Coast University Hospital, Queensland, Australia
4 School of Medicine, Bond University, Queensland, Australia
Abstract
Periprocedural anticoagulation continues to be a vital aspect in the management of coronary artery 
disease. Bivalirudin is a relatively new drug that has caught much attention in the last decade, espe-
cially in the context of percutaneous coronary intervention for acute coronary syndromes. Multiple 
clinical trials have shown the efficacy, safety profile and limitations of bivalirudin in contrast to 
previously used heparin and glycoprotein IIb/IIIa inhibitors. These trials have included patients 
with moderate to high-risk stable angina, unstable angina, non-ST-elevation and ST-elevation myo-
cardial infarctions requiring PCI. The growing body of evidence on bivalirudin has also improved 
the understanding of its applicability and efficacy over other hirudin-based anticoagulants, however 
continual review of more recent evidence is important in order to integrate bivalirudin more widely 
across the various guidelines. This article aims to study the cross-section of the evidence base to date 
on the clinical use, efficacy and risks related to the use of bivalirudin and attempts to provide the 
clinician with a practical overview of the role of bivalirudin in the most recent guidelines.
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Introduction
New and novel agents targeting the anticoagulation cascade are finding increasing prevalence on the 
world stage of late not only in clinical trials but also within recent therapeutic guidelines.
Bivalirudin is a reversible direct thrombin inhibitor that has shown rapid integration into modern 
management of acute coronary syndromes (ACS) due to its strong clinical data and reduced side ef-
fect profile [1]. Since their emergence, direct thrombin inhibitors have shown several pharmacologi-
cal advantages over other agents such as unfractionated heparin and glycoprotein IIb/IIIa inhibitors. 
Bivalirudin in particular has taken a versatile role, ranging from the treatment of unstable coronary 
artery disease to high-risk acute coronary syndrome [2-7]. Bivalirudin was discovered by The Medi-
cines Company and approved by the FDA in 2000 [1]. It is currently being marketed under the trade 
name of Angiomax® in the United States. Other international trade names include Angiox®, Bivaflo® and 
Bivasave® [1].
Bivalirudin binds directly to circulating and clot-bound thrombin [2]. This prevents the cleavage of fi-
brinogen and inhibits activation of coagulation factors V, VIII, XIII and platelet aggregation, inhibiting 
clot formation [8]. The primary goals of therapy with bivalirudin are to prevent thrombotic occlusion 
of diseased vessels, thrombus propagation and myocardial ischaemia whilst achieving an acceptable 
balance with complications such as bleeding [2,9].
Through bivalirudin’s rapid uptake into clinical guidelines it is quickly becoming an appealing alterna-
tive to traditional anticoagulation regimes in the setting of percutaneous intervention for both ST ele-
vation (STEMI) and non-ST elevation myocardial infarction (NSTEMI). It is also effective in the medi-
cal management of moderate to high-risk unstable angina and NSTEMI. This article aims to review the 
effectiveness of bivalirudin for percutaneous coronary intervention following STEMI, moderate-high 
risk NSTEMI and unstable angina.
Molecular mechanism: the pharmacodynamics 
and pharmacokinetics of bivalirudin
Bivalirudin is a semi-synthetic analogue of a protein named hirudin, which was originally discovered 
in the salivary gland of the medicinal leech [8]. Like other hirudin based molecules, bivalirudin’s pri-
mary effect is on the anticoagulation cascade, which is vital to its utilisation in cardiovascular medicine.
The coagulation process is initiated by a complex interaction between the intrinsic and extrinsic factors 
found in plasma. The extrinsic activation occurs when vascular injury causes tissue factor to be expo-
sed on endothelial cells, promoting the interaction with factor VII [9]. This contributes to the serial 
activation of the intrinsic factors and eventually results in the activation of thrombin [9]. Thrombin 
is vital to the clotting cascade due to its role in fibrinogen cleavage, cross-link formation and clot sta-
bilisation. Normally, equilibrium is achieved between the natural procoagulants and anticoagulants 
preventing spontaneous clot formation. However, thrombus formation is promoted by variations in 
flow turbulence, blood constituents and damage to the vascular endothelium [8,9].
Bivalirudin is a peptide molecule consisting of 20 amino acid residues and contains two different bin-
ding sites – the fibrin-binding site or exosite 1 (competitive inhibition) at the carboxy-terminus and the 
active site at the amino-terminus [9]. It acts by binding directly to the thrombin protein via both these 
binding sites, without the need for any cofactors. It binds to both free and fibrin-bound thrombin with 
an intermediate affinity between hirudin and argatroban [9,12]. Its main role is to inhibit the activation 
of factors V, VIII and XIII and prevents the thrombin-mediated cleavage of fibrinogen to fibrin, thus 
preventing thrombus formation [8,9].
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Bivalirudin is preferred over other anticoagu-
lants due to it predictability which is explained 
by the linear dose-dependent pharmacokinetic 
property [9]. It can only be administered as an 
intravenous bolus or infusion and has a small 
volume of distribution (0.2 l/kg), which suspen-
ds it predominantly in the intravascular space 
[9]. The peak plasma concentration is achieved 
within 5 minutes of bolus infusions [1] and the 
onset of action is immediate. Whilst active in 
the system, bivalirudin causes a prolongation of PT, aPTT, thrombin time (TT) and activated platelet 
time (ACT) in a linear dose-dependent fashion [1,15,16]. The anticoagulation effect of bivalirudin can 
be monitored by checking ACT following PTCA, PCI or during CABG [9,13]. But in most catheterisa-
tion laboratories ACT is not monitored routinely with the use of bivalirudin.
Bivalirudin has a short half-life of approximately 25 minutes. Upon cessation, it is rapidly cleared from 
plasma at a rate of 4 ml/min/kg via a dual clearance system and baseline-clotting times are achieved 
within 1 hour in patients with normal renal function [9]. It is metabolised predominantly through 
proteolytic cleavage by thrombin at the active site [14], which dislodges the molecule from both sites. 
As a result, binding at the active site is transient and allows for easier reversibility compared to other 
hirudins like lepirudin and desirudin. [10,11,12] Apart from the proteolytic cleavage, which accounts 
for 80% of bivalirudin’s metabolism [17], renal excretion contributes to the remaining 20% and hepatic 
involvement is virtually negligible [12,15]. For this reason, bivalirudin requires dose adjustment in 
renal impairment (Table I) but not hepatic dysfunction [17].
Indications
Bivalirudin was first approved by the FDA as an effective anticoagulant during PCI or PTCA for un-
stable angina, where its anticoagulant effect was used to prevent thrombus formation in the peri-pro-
cedural period and subsequent complications of cardiac ischaemia [1]. However, since then it has been 
most commonly used in ST elevation myocardial infarction and moderate to severe non-ST elevation 
myocardial infarction. In addition, bivalirudin has been approved for acute coronary syndromes in 
patients with or at risk of heparin induced thrombocytopaenia (HIT) undergoing PCI [1-4].
Although some studies have shown positive effects of bivalirudin in patients with acute or sub-acute 
HITS requiring urgent cardiopulmonary bypass surgery, the evidence is still minimal and FDA appro-
val is still pending for this use [1]. The use of bivalirudin for medical management of acute coronary 
syndromes is also being studied currently, but once again the lack of adequate evidence limits its appli-
cation in this setting [1].
Efficacy and evidence from pivotal trials
Compared to other well-known anticoagulants, bivalirudin is a relatively new agent on the market. Since 
its development in 2000, it has been the subject of many pivotal trials that have investigated its efficacy, ap-
plicability and limitations (Table II). Some of the earliest trials that brought direct thrombin inhibitors into 
the limelight also investigated the efficacy of other hirudins such as lepirudin and desirudin. Although 
these hirudins showed some efficacy in the management of thromboembolic disease and anticoagulation 
in patients with HITS, bivalirudin has shown the most effective results for acute coronary syndromes.
Renal Function 
(ml/ min)
Initial bolus 
(mg/kg)
Infusion rate for 
PCI (mg/ kg/h)
Half-life 
(min)
Clcr ≥ 30 0.75 1.75 25
Clcr 10-29 0.75 1.25 60
Dialysis 
dependent
0.75 0.25 240
Table I. Dose-adjustments in renal 
impairment [1]
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HORIZONS-AMI Trial
In this trial [18], 3602 patients with ST-elevation myocardial infarction who presented within 12 hours 
of the onset of symptoms and were undergoing primary PCI were recruited. Patients were either given 
bivalirudin alone or a combination of heparin and glycoprotein IIb/IIIa inhibitor using a randomised 
but open-label method. The primary end point events were major bleeding and major cardiovascular 
events including stroke, re-infarction, revascularisation and death. This study found that the bivaliru-
din group, compared to the heparin and GP IIb/IIIa group, had a reduced 30-day rate of net adverse 
events (9.2% vs. 12.1% respectively, relative risk = 0.76, p-value < 0.005). Majority of the risk reduction 
was attributed to significantly lower rates of major bleeding (4.9% vs. 8.3%, relative risk = 0.60, p-value 
< 0.001). Bivalirudin was also responsible for a significant reduction in 30-day mortality from both 
cardiac causes (1.8% vs. 2.9%, relative risk = 0.62, p-value < 0.03) and all-cause mortality (2.1% vs. 
3.1%, relative risk = 0.66, p-value = 0.047). One disadvantage of bivalirudin that was discovered by 
this trial was the increased risk of acute stent thrombosis within 24 hours of the procedure (1.3% vs. 
0.3%, p-value < 0.001), however no significant increase was seen at 30 days. In conclusion, this study 
demonstrated that although the early stent thrombosis was the main contributor to the increased risk 
of cardiovascular events in the first 24 hours post-procedure, overall benefit was seen in patients trea-
ted with bivalirudin in terms of reduced risks of major and minor bleeding, need for transfusions and 
incidence of net adverse events at 30 days. It is therefore proposed that bivalirudin is a suitable alter-
native to heparin for patients with acute ST-elevation myocardial infarction undergoing primary PCI, 
regardless of whether they have received heparin prior to the procedure.
Aim
Bivalirudin + 
GP IIb/ IIIa inhibitor
Heparin + 
GP IIb/ IIIa inhibitor
Bivalirudin 
alone
P-value
HORIZONS-AMI [18]
Net adverse effects 12.1% 9.2% < 0.05
Major Bleeding 8.3% 4.9% < 0.001
Mortality due to cardiac causes at 30 days 2.9% 1.8% > 0.03
Acute stent thrombosis 0.3% 1.3% < 0.001
REPLACE-2 [19,20]
MI at 30 days 7.0% 6.2% < 0.001
Haemorrhage 2.4% 4.1% < 0.001
Urgent revascularisation 1.2% 1.4% < 0.001
Overall mortality at 12 months 1.9% 2.5% < 0.001
ACUITY [21]
Ischemic events 6.2% 5.5% 0.47
Major bleeding 2.5% 4.9% < 0.001
Net clinical outcomes 8.0% 9.4% 0.17
ISAR-REACT 4 [22]
Major Bleeding 4.6% 2.6% 0.02
Severe Thrombocytopaenia 1.2% 0.0% -
BAT-2 [23]
Bleeding 3.5% 9.3% 0.039
Combined end point 6.2% 7.9% < 0.001
Table II. Summary of results from pivotal trials [18-23]
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REPLACE-2 trial
This trial [19,20] demonstrated the efficacy of bivalirudin in 6002 patients undergoing PCI in four key 
categories:
 • unstable angina;
 • myocardial infarction 7 days prior to procedure;
 • stable angina and;
 • patients with a positive exercise stress test for ischaemia.
It was a double-blinded, randomised control trial where patients were either administered a combi-
nation of bivalirudin and provisional GP IIb/IIIa inhibitor (abciximab) or heparin and GP IIb/IIIa 
inhibitor (abciximab). Major outcomes measured were rates of death, myocardial infarction and urgent 
revascularisation.
At 30 days, patients were found to have higher rates of MI (7.0% vs. 6.2%, p-value < 0.001) and the 
combined rates of these endpoints were higher in the bivalirudin group (7.6% vs. 7.1%, p-value < 
0.001). However, overall mortality rate was lower in the bivalirudin group (0.2% vs. 0.4%, p-value < 
0.001) as were the rates of major haemorrhage (2.4% vs. 4.1%, p-value < 0.001) and urgent revascu-
larisation (1.2% vs. 1.4%, p-value < 0.001). At the 12-month follow-up, patients in the bivalirudin 
group were again found to have lower mortality rates when compared to the heparin and GP IIb/
IIIa inhibitor group (1.9% vs. 2.5%, p-value < 0.001). This study found that major bleeding was a 
far more powerful predictor of death than cardiovascular events. Major haemorrhage was defined 
as intracranial bleeding, retroperitoneal bleeding, need for transfusion of at least 2 or more units of 
blood products, a fall in haemoglobin by > 4 g/dl or >3g/dL with spontaneous and non-spontaneous 
blood loss.
Another analysis from the REPLACE-2 trial confirmed that mortality rates in patients with major hae-
morrhage were significantly higher than in those without at 30 days (5.1% vs. 0.2%), 6 months (6.7% 
vs. 1.0%) and 1 year (8.7% vs. 1.9%, p-value<0.001 for all).
Bivalirudin showed the potential to reduce the risk of haemorrhagic complications and was therefore a 
suitable replacement for heparin across all acute coronary syndromes.
ACUITY trial
The ACUITY [21] is another hallmark trial in bringing bivalirudin into the foreground of cardiova-
scular medicine. This trial was designed to be a prospective randomised controlled trial and recruited 
13,819 moderate and high-risk patients with unstable angina or non-ST elevation myocardial infarc-
tion. They were then randomly allocated to one of the following groups- UFH/enoxaparin with GP 
IIb/IIIa inhibitor, bivalirudin with provisional GP IIb/IIIa inhibitor, bivalirudin alone and in some 
cases patients were switched from a pre-treatment of UFH/enoxaparin to bivalirudin. The primary end 
points observed were rates of ischaemic events, major bleeding and net clinical outcomes.
Compared to patients who received heparin and GP IIb/IIIa inhibitor, the patients with bivalirudin 
therapy had similar rates of ischaemia (bivalirudin vs. Heparin: 6.2% vs. 5.5%, p = 0.47), lesser rates of 
major bleeding (2.5% vs. 4.9%, p < 0.001) and similar net clinical outcomes (8.0% vs. 9.4%, p = 0.17). In 
addition, it was found that those patients who switched from pre-treatment with heparin to bivalirudin 
had similar rates of ischaemic events compared to those who continued on UFH/enoxaparin (6.9% vs. 
7.4%, p = 0.52). They also had a lower rate of major bleeding (2.8% vs. 5.8%, p < 0.01) and improved 
clinical outcomes (9.2% vs. 11.9%, p < 0.01).
This trial provided a significant insight into more flexible applicability of bivalirudin, especially in the 
setting of pre-treatment with other antithrombin agents and reinforced a conclusion reflected in pre-
vious trials: bivalirudin is as effective as heparin and GPIIb/IIIa inhibitor in preventing net ischemic 
events and significantly superior in reducing bleeding risks and complications.
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ISAR-REACT 4 trial
In this study [22] the aim has been to assess the efficacy and applicability of bivalirudin, in contrast 
to a combination of unfractionated heparin and GP IIB/IIIa inhibitor (abciximab), in patients with 
non-ST elevation MI undergoing PCI. The trial was carried out in a double-blind manner recruiting 
1,721 patients with acute non-ST elevation MI who were assigned to each of the two treatment groups 
equally. The primary end points that were measured were death, recurrent MI, urgent target-vessel 
revascularisation and major bleeding within 30 days. It was found that there was no significant diffe-
rence between the two groups in the occurrence of primary end points (relative risk = 0.99, p-value = 
0.94). However, the incidence of major bleeding was found to be significantly lower in the bivalirudin 
group (2.6% vs. 4.6%, relative risk = 1.84, p-value = 0.02). This was predominantly due to an increased 
frequency of TIMI minor bleeding rather (p = 0.003) than TIMI major bleeding (p = 0.61). Severe 
thrombocytopaenia was another complication seen in the abciximab and heparin group (1.2%), which 
was absent in the bivalirudin group. This also highlighted that bivalirudin is a safer choice in throm-
bocytopaenic patients with or without HITS as opposed to abciximab and heparin, as both these agents 
have been found to worsen this condition. This trial concluded that bivalirudin is equally as effective 
in preventing cardiovascular events and death and significantly superior to unfractionated heparin and 
abciximab in term of major haemorrhagic risks.
BAT-2 trial
The aim of this trial [23] was to evaluate the effect of bivalirudin in patients with unstable angina 
who were undergoing PTCA, using a double-blinded, multicentre, randomised trial. A group of 4,312 
patients with unstable angina or post-MI angina were treated with either bivalirudin or high-dose he-
parin in the peri-procedural period. The efficacy endpoints comprised of death, MI, urgent revasculari-
sation and impending or abrupt target vessel closure. The safety endpoint was major haemorrhage. The 
results of this study showed that the combined rates of endpoint were similar between the bivalirudin 
group and the heparin group (6.2% vs. 7.9%, p-value = 0.039) at 7 days. This was found to be the same 
at 90 days (p = 0.012) and 180 days (p = 0.153). However, significant difference was seen in the bleeding 
risk with bivalirudin showing less risk than heparin (3.5% vs. 9.3%, p < 0.001). This demonstrates that 
although the efficacy was non-inferior to heparin, the safety profile of bivalirudin is significantly better 
than heparin during PTCA for patients with unstable or post-MI angina.
Complications and safety
Haemorrhagic complications
Following the administration of bivalirudin, bleeding (minor and major collectively) continues to be 
the most notable complication [9,18]. Major bleeding was initially defined in the developmental trials 
of bivalirudin as follows:
 • intracranial or retroperitoneal haemorrhage;
 • clinically overt bleeding causing a reduction in haemoglobin of more than 3 g/dl;
 • clinically overt bleeding leading to transfusion of 2 or more units of blood.
In addition to this, some of the pivotal trials (REPLACE-2 and ACUITY) included other measures such 
as haemorrhage at access site, haematoma greater than 5 cm and need for haemorrhage-controlling 
procedures to measure the extent of this complication [18,19].
The ACUITY trial demonstrated that there was a significant rise in overall mortality at 30 days in pa-
tients who had major haemorrhage as opposed to those who did not (7.3% vs 1.2%; p < 0.0001) [21]. 
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Due to these staggering results, monitoring of clotting times and regular assessment for bleeding is a 
vital part of patient care following bivalirudin.
Monitoring levels
The activated clotting time (ACT) has previously been used for monitoring coagulation profile of pa-
tients on bivalirudin [24]. More recent studies have experimented with Ecarin clotting time (ECT) as 
opposed to the ACT. Although multiple studies have showed that ECT has shown a better correlation 
to bivalirudin concentrations in plasma compared to ACT [25], further evidence is required before it 
is implemented in clinical practice. Currently, the availability of ECT at laboratories is also limited [1].
Acute stent thrombosis
The results from the HORIZONS-AMI trial revealed that the patient group that was treated with bi-
valirudin was at a significantly higher risk of stent thrombosis within 24 hours of the PCI procedure: 
bivalirudin alone 1.3% vs. heparin and GP IIb/IIIa 0.3%, p < 0.001 [18]. This is a feared complication 
by most cardiologists, and if reduced, could further promote the use of bivalirudin in patients requi-
ring PCI. A recent multi-centre study found that continuing a 2-hour infusion of bivalirudin post-PCI 
reduces the risk of acute stent thrombosis whilst maintaining the low bleeding risk: 0.7% experienced 
acute stent thrombosis and 1.7% had major bleeding post PCI [26]. Further studies are currently being 
carried out to identify more strategies to reduce the rates of acute stent thrombosis in patients who have 
been anticoagulated using bivalirudin.
Overdose
Bivalirudin has a wide therapeutic range with single bolus doses of up to 7.5 mg/kg being tolerated 
without any associated bleeding or other adverse effects [1]. In the event of an overdose, bivalirudin 
infusions and boluses must be immediately stopped [1]. Due to the short half-life, plasma levels are cle-
ared rapidly [9]. There are currently no effective antidotes available for bivalirudin overdose, however 
clearance can be promoted by haemodialysis [9]. Following an overdose it is advised that patients are 
monitored for signs of haemorrhage and ACT levels are checked regularly [1].
Hypersensitivity
Like all medications, bivalirudin has a possibility for anaphylactic reaction. However, the likelihood 
of this occurring is less than 1% in a given population [9]. This medication does not contain immu-
nological compounds such as antibodies or any common allergenic materials (e.g. egg protein, bovine 
products etc.) [1,9].
In one particular study, it was found that the drug did not promote any antibody formation at 7 and 
14 days in patients treated with bivalirudin [9,14]. Another trial tested bivalirudin-treated patients 
for anti-bivalirudin antibodies [9,14]. Out of the 11 patients who showed positive results, 9 were false 
positives and the remaining two could not be retested [9,14]. These patients did not have any anaphy-
lactic reactions in response to the drug [9,14]. Caution must still be taken if the patient has previously 
experienced any adverse drug reactions to hirudin molecules and the drug must be ceased upon any 
abnormal reactions to the medication.
Other common adverse reactions
Some of the more common adverse reactions seen in patients treated with bivalirudin include hypoten-
sion, nausea, generalized pain, headaches and injection site irritation [9,18].
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Safety related to CABG procedure
Since its initial popularity with PCI, bivalirudin has been the subject of many trials, which have investi-
gated its application in the setting of on-pump cardiopulmonary bypass (CPB) and off-pump coronary 
artery bypass graft (OPCAB) surgeries.
EVOLUTION-OFF was an open label, multicenter study involving a population size of 157 patients, 
who were randomly assigned to receive either bivalirudin or heparin during their OPCAB [27]. The 
regime for bivalirudin was the same as what is routinely used during PCI: 0.75 mg/kg bolus, followed 
by 1.75 mg/kg/h infusion for the duration of the procedure. The primary end point observed was acute 
procedural success. This was defined as absence of death, Q-wave MI, repeat coronary revasculariza-
tion and stroke at day 7 or upon discharge, and occurred in 93% of patients in both groups. There was 
a significantly higher number of stroke in the heparin group (5.5% vs. 0%) however, haemorrhagic risk 
was similar in both groups [27].
Since then multiple trials have also tested the use of bivalirudin for on-pump cardiac bypass surgery 
and focused on the same primary end points as the EVOLUTION-OFF trial. 101 patients were recrui-
ted and randomized to bivalirudin or heparin. It was found that no significant difference in the primary 
end point data across the two groups up to 7 days follow up [9]. Rate of post-operative bleeding was 
greater with bivalirudin at 2 hours (238 ml vs. 160 ml, p = 0.0009) and a higher risk of reoperation to 
control bleeding [9]. This was offset by lower tendency of perioperative non-Q wave MI in the bivaliru-
din group [9]. The results of these trials showed that bivalirudin has the potential to be a replacement 
for heparin during CPB [9]. This was further emphasized by the CHOOSE trials where the safety 
and efficacy of bivalirudin was evaluated in comparison to heparin, in patients with heparin induced 
thrombocytopaenia (HIT) [28]. With a procedural success of 94% receiving bivalirudin, it was con-
cluded that bivalirudin is a preferred alternative anticoagulant for patients with HIT requiring cardiac 
surgery [28].
Comparison with abciximab
Abciximab is a potent intravenous glycoprotein IIb/IIIa inhibitor that became prominent in cardiova-
scular medicine in the early 1990s. Since then, its antiplatelet effect has been widely used in the mana-
gement of acute coronary syndromes, especially in the setting of percutaneous coronary intervention. 
Abciximab prevents the binding of adhesive molecules such as von Willebrand factor and fibrinogen 
to the Gp IIb/IIIa receptor, ultimately preventing platelet cross-link formation and platelet aggregation 
[9].
Many pivotal trials including EPIC, EPILOG, EPISTENT have shown the superiority of abciximab over 
placebo and heparin in the setting of PCI or angioplasty, in terms of 30-day mortality and AMI rates. 
However, HORIZONS-AMI, ACUITY, ISAR REACT 4 and REPLACE-2 have compared the effect of 
bivalirudin and GP IIb/IIIa inhibitor (abciximab). The results from these trials are showed following.
 • HORIZONS-AMI [18]:
 • significant decreases in net adverse effects (9.2% vs. 12.1%) and major bleeding (4.9% vs. 8.4%) 
at 30 days and up to 2 years;
 • early stent thrombosis (< 24h) was higher by 1% in the bivalirudin group but no significant 
difference between 30 days to 2 years.
 • ACUITY & ISAR-REACT 4 [21,22]:
 • no significant rise in net adverse effects at 30 days;
 • lower rates of bleeding in the bivalirudin group.
 • REPLACE-2 [19,20]:
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 • significant reduction in rates of major bleeding with bivalirudin (2.4% vs. 4.1%).
 • reduction in mortality rates by 24% in the bivalirudin group which persisted up to 12 months.
GUSTO V and FINESSE trials also investigated the application of abciximab for thrombolysis and 
collectively found that there was no significant mortality benefit but the risk of major bleeding and 
transfusion rates was higher [29].
Abciximab also carries a risk of thrombocytopaenia in addition to the risk of heparin-induced throm-
bocytopaenia from co-administered heparin [30]. The mechanism for this is thought to be due to im-
mune-mediated response to the amino acid residues of the monoclonal antibody once it has interacted 
with the receptor [29,30]. A pooled analysis of eight randomised trials found that abciximab increased 
the incidence of mild (4.2% vs. 2%) and severe thrombocytopaenia (1% vs. 0.4%) when compared to 
placebo [31]. Bivalirudin does not carry this risk, therefore is a suitable choice in patients with or at risk 
of thrombocytopaenia from any cause [9].
In contrast to the evidence supporting the use of bivalirudin prior to cardiac surgery in multiple trials, 
abciximab has been shown to carry a significant increase in bleeding complications and mortality, even 
up to 6 hours post-cessation of the drug [31]. Patients whose procedure was complicated by bleeding 
required up to 6 units of packed red cells, 30 units of platelets and 8 units of fresh frozen plasma peri-
operatively [31-36]. These trials have had variable results and although recent abciximab infusion is not 
a contra-indication to emergent cardiac surgery, it contributes to a higher bleeding risk and therefore 
demands greater peri-operative monitoring [32-34].
Evidence from current era: the EUROMAX study
In the recently published EUROMAX study [37] that compared bivalirudin therapy with heparin and 
optional GP IIb/III a inhibitor initiated in the ambulance in patients presenting with STEMI who were 
taken for primary PCI, there was a 40% relative risk reduction and more than a 3% absolute reduction 
in the risk of major bleeding or death at 30 days (5.1% vs. 8.5%, RR = 0.60, 95% CI: 0.43-0.82, p = 0.001) 
in the bivalirudin treatment arm.
There was a 28% relative risk reduction in the secondary triple outcome measure of death, re-infarc-
tion, or non-CABG major bleeding; 6.6% versus 9.2% (RR = 0.72, 95% CI = 0.54-0.96, p = 0.02). This 
result that was driven by a 57% relative risk reduction in major bleeding, 2.6% versus 6.0% (RR = 0.43, 
95% CI: 0.28-0.66, p < 0.001). In this study the risk of acute stent thrombosis was 1.1% vs. 0.2% (95% 
CI: 1.37-27.24, p = 0.007) in the bivalirudin arm.
This study replicated the observations made in the previous studies in a modern-day context characte-
rized by the optimal use of novel P2Y12 receptor blockers, discretionary use of GPIIb/IIIa inhibitors, 
radial access and early initiation of treatment [37].
Current guidelines for the use of bivalirudin
ACC/AHA 2013 updated guidelines for STEMI
The focused update of the ACC/AHA guidelines for the management of STEMI from 2013 acknowled-
ged that bivalirudin is a reasonable alternative anticoagulant for heparin in those STEMI patients who 
receive fibrinolysis with streptokinase, have heparin-induced thrombocytopaenia or who, in the opi-
nion of the physician, may benefit from anticoagulation [38]. This applies to the setting of primary PCI 
and regardless of whether the patient received pretreatment with UFH or not (Table III) [39].
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Based on the HERO-2 trial, it is advised that the regimen of 0.25 mg/kg bolus is followed by an intrave-
nous infusion of 0.5 mg/kg per hour for the first 12 hours and 0.25 mg/kg per hour for the subsequent 
36 hours shows optimum efficacy. It is also recommended that a reduction in the infusion rate be con-
sidered if the PTT is above 75 seconds within the first 12 hours [38-40]. However, it was advised that 
prospective studies be reviewed in order to understand the risk of acute and subacute stent thrombosis 
associated with the use of bivalirudin as previous results had confounding bias posed by concurrent use 
of UFH or clopidogrel. Class I recommendation (Level of evidence: B) [38,39].
Bivalirudin is also considered a reasonable choice of anticoagulation for STEMI patients with high risk 
of bleeding undergoing PCI. Class II recommendation (Level of evidence: B) [38,39].
ESC guidelines for STEMI 2012
The European guidelines also include bivalirudin as an effective anticoagulant for acute myocardial 
infarctions [41]. Following the review of the hallmark and some more recent trials, the 2012 guidelines 
have highlighted that a combination of bivalirudin and GP IIb/IIIa inhibitors is preferred to unfractio-
nated heparin and GP IIb/IIIa inhibitors in the setting of a ST elevation myocardial infarction [41]. It 
is once again advised that the dosing regimen be followed. Class I recommendation (Level of evidence: 
B) [41].
2011 AACF/AHA/SCAI guideline for percutaneous coronary intervention
It has been recommended that for patients undergoing PCI, bivalirudin is a useful anticoagulant with 
or without prior treatment with UFH (Class I recommendation, Level of evidence: B) [42]. It is also 
accepted for use in patients at risk of or have heparin-induced thrombocytopaenia, as a replacement 
for UFH (Class I recommendation, Level of evidence: B) [42]. These recommendations were based on 
the recent literature supporting bivalirudin lower bleeding risk in the short term, however, caution is 
advised for a small increase in the risk of early ischaemic events [42].
Conclusion
For patients with acute coronary syndrome, early revascularization with PCI in combination with 
antiplatelet and antithrombotic therapies provide the best prognosis. Several anticoagulants have 
been trialed over the years and whilst some have been impressively efficacious newer agents in the 
market warrant for frequent updates and reviews of the current guidelines. Bivalirudin is a relatively 
new drug that has proven beneficial in the setting of coronary intervention for STEMI, NSTEACS 
and moderate to high-risk stable IHD [1]. Bivalirudin is a hirudin-based anticoagulant, which works 
by interfering with the activation of clotting factors, and thereby, limiting the cleavage of clot based 
Bivalirudin is a reasonable choice for use in PCI in patients Recommendation Level of evidence
With or without pretreatment with UFH or clopidogrel I B
Who received fibrinolytic treatment with streptokinase I B
Who have heparin-induced thrombocytopaenia I B
Who have high risk of bleeding II B
Table III. Summary of the recommendations for the use of bivalirudin according to the ACC/AHA 
Guidelines for the management of STEMI [38,39]
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and circulating thrombin and the subsequent coagulation process [8,9]. Compared to other antico-
agulants, the side effects of bivalirudin are far less, with major bleeding being the most significant 
one [9].
Several hallmark trials have revealed that bivalirudin is comparable to heparin and GP IIb/IIIa inhibi-
tors in terms of preventing cardiac ischaemia. However, the benefit of bivalirudin is predominantly in 
reduction of risk of major bleeding, overall mortality and HITS associated complications [18-23]. Bi-
valirudin is also considered a safe replacement for UFH in patients requiring CABG procedure [27,28]. 
The reduced risk of HITS is an additional benefit of bivalirudin that has especially promoted its use in 
patients with or at risk of HITS [28]. Despite its recent emergence, bivalirudin has been incorporated 
into the current cardiac guidelines and continues to be the subject of ongoing research and deve-
lopment to yield more applicability in the field of cardiology.
The review in brief
Clinical 
question
This article reviews the cross-section of the evidence base to date on the clinical use; efficacy and risks 
related to the use of bivalirudin and attempts to provide the clinician with a practical overview of the role 
of bivalirudin in the most recent guidelines.
Type of 
review
Narrative
Conclusions Bivalirudin is a direct thrombin inhibitor that has shown significantly superior benefits in efficacy and safety. 
There is a growing evidence base for the efficacy, safety profile and limitations of bivalirudin relative to the 
traditional agents such as heparin and glycoprotein IIb/IIIa inhibitors. The evidence base covers the full 
spectrum of the acute coronary syndrome requiring percutaneous intervention (PCI) that include moderate 
to high-risk stable angina, unstable angina, non-ST-elevation and ST-elevation myocardial infarctions 
requiring PCI. The predictable pharmacodynamics and pharmacokinetics, rapid onset and offset of action 
and significantly low bleeding risk highlight the advantages of this agent. Early stent thrombosis (within 
the 1st 24-hours) observed in some trials was a serious concern. Some authorities advocate the practice of 
continuing the infusion for 2 hours after the interventional procedure to address this issue. The growing 
evidence base supporting the use of this agent has resulted in its preferred recommendation in the latest 
guidelines published by the peak bodies for the management acute coronary syndrome. Furthermore the 
cost efficacy compared to the combined use of heparin with GP2b3a inhibitors makes this an economically 
viable alternative.
Limitations Lack of evidence for the use of this agent in the setting of acute coronary syndrome.
Questions for further research
The evidence base at hand is convincing enough to recommend bivalirudin as an alternative to 
heparin together with GPIIbIIIa inhibitors in the management of acute coronary syndrome in the 
catheterization laboratory. However there are practical questions yet to be answered in other are-
as where anticoagulation and antithrombotic therapy is required. More research is required to 
examine the benefit of bivalirudin as an alternative to traditional anticoagulants in the setting of 
medical management of acute coronary syndrome. Furthermore research in the future may shed 
light into its use in coronary artery by pass surgery, cardiac valve surgery, and the treatment of 
thromboembolic conditions such as pulmonary embolism. Heparin is commonly used for bridging 
of anticoagulant therapy for surgery in those on long-term oral anticoagulant therapy. More re-
search in the future may examine the use of bivalirudin for this application too.
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